Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Excerpt from the Press Release:

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA.

“These data add to a growing body of evidence outlining the clinical value of DAWNZERA for people living with HAE, highlighting its potential to deliver meaningful improvement in HAE attack rate and quality of life, including for those switching from another long-term prophylactic therapy,” said Kenneth Newman, M.D., senior vice president, clinical development, Ionis. “We know that patients continue to seek out a treatment that meaningfully reduces attack frequency and severity while also addressing the administration and lifestyle burden of long-term therapy. The breadth of data being presented at AAAAI underscores the potential for DAWNZERA to meet these needs and to be the prophylactic treatment of choice for many people living with HAE.”

Ionis will have eight poster presentations, as follows. All final posters are available on the Ionis website.

• Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks: Findings from the OASISplus Study
  • Poster Presentation: February 27, 2026, 2:45-3:45 pm (Poster 163)
  • Presenting Author: Marc Riedl

Click the button below to read the entire Press Release:

Continue Reading The Press Release